David Fellows appointed as Chairman of the Board

  • David Fellows appointed as Chairman of Oxular’s Board of Directors
  • David has more than 30 yearsof experience in various leadership roles within the ophthalmic pharmaceuticalindustry

10 January 2017 – Oxular Limited, the Oxford-based retinal therapeutics company, today announces the appointment of David Fellows, previously Non-Executive Director, as the Company’s Chairman of the Board. Mr. Fellows will replace Dr. Nigel Pitchford, who will continue on Oxular’s Board as a Director.

David Fellows brings a wealth of ophthalmology and organisational leadership experience to Oxular. He is currently Chief Executive Officer of NightstaRx Limited, a private biopharmaceutical company specialising in developing ocular gene therapies for patients with inherited retinal dystrophies. He was previously Vice President of Johnson & Johnson’s Vision Care Franchise where he led global marketing, new product and licensing activities. Prior to that he was employed at Allergan for 25 years where he served in a number of sales and marketing roles, including Regional President, Corporate Vice President and Senior Vice President in locations in North America, Europe and Asia.

Tom Cavanagh, Chief Executive Officer of Oxular Limited, commented:

“We welcome David as Chairman of our board. We believe that with his expertise in the ophthalmic industryDavid will play akey role in helping us to achieve our goal of building a global ophthalmic franchise developing innovative treatments for retinal diseases. I would also like to take this opportunity to thank Nigel Pitchford for his invaluable leadership during Oxular’s first year of operations and am pleased that we will continue to benefit from his experience as a Board Director.”

David Fellows, Chairman of the Board of Oxular Limited, commented:

“I am delighted to be appointed Chairman at this exciting time in the Company’s development. Oxular is committed to utilising its expertise to develop and register novel therapies for treating patients with sight-threatening retinal diseases. We have a talented team and I look forward to working with them as we advance our product portfolio.”

Scroll to Top